Applicant, as named in the Orange Book

Sumitomo Pharma Am

Next listed expiry: Aptiom on 24 Aug 2032. 4 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Aptiom · 4 strengths eslicarbazepine acetate	eslicarbazepine acetate	022416	24 Aug 2032	patent, carve-out possible
Orgovyx relugolix	relugolix	214621	29 Sep 2037	patent, carve-out possible
Gemtesa vibegron	vibegron	213006	6 Jul 2042	patent, carve-out possible
Myfembree estradiol; norethindrone acetate; relugolix	estradiol; norethindrone acetate; relugolix	214846	5 Nov 2042	patent